Heparin ameliorates pulmonary hypertension induced by platelet- activating factor in pigs

Thrombosis Research

Volumn 90, Issue 5, 1998, Pages 223-228

  Karlsson, Helena ^a   Abu Zidan, Fikri M ^b   Walther, Sten ^a   Lennquist, Sten ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Haemodynamics; Heparin; Platelet activating factor

Indexed keywords

GINKGOLIDE B; HEPARIN; LEXIPAFANT; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOPULMONARY HEMODYNAMICS; CARDIOVASCULAR AUTOREGULATION; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SWINE; THROMBOCYTE ACTIVATION;

ANIMALS; ANTICOAGULANTS; DRUG ANTAGONISM; FEMALE; HEPARIN; HYPERTENSION, PULMONARY; INJECTIONS, INTRAVENOUS; MALE; PLATELET ACTIVATING FACTOR; SWINE;

EID: 0032103544     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00064-4     Document Type: Article

References (27)

1. 1. Benveniste J, Henson PM, Cochrane CG. Leucocyte dependent histamine release from rabbit platelets: The role of IgE, basophils and a platelet-activating factor. J Exp Med 1972; 136:1356-77.
2. 2. Venable ME, Zimmerman GA, McIntyre TM, Prescott SM. Platelet-activating factor: A phospholipid autoacid with diverse actions. J Lipid Res 1993;34:691-702.
3. 3. Abu-Zidan FM, Walther S, Lennquist S. BB-882 is a potent antagonist of the haemodynamic changes induced by platelet-activating factor in pigs. Pharmacol Toxicol 1996;78:23-7.
4. 4. Laurindo FRM, Goldstein RE, Davenport NJ, Ezra D, Feuerstein GZ. Mechanism of hypotension produced by platelet-activating factor. J Appl Physiol 1989;66:2681-90.
5. 5. Filep J, Herman F, Braquet P, Mózes T. Increased levels of platelet-activating factor in blood following intestinal ischemia in the dog. Biochem Biophys Res Commun 1989;158: 353-9.
6. 6. Abu-Zidan FM, Walther S, Lennquist S. Role of platelet-activating factor on cardiovascular dysfunction in postischemic shock in pigs. Eur Surg Res 1997;29:133-41.
7. 7. Sagach VF, Dmitrieva AV, Braquet P. Pooling of blood in postischemic shock is modulated by platelet-activating factor (PAF). Lipids 1991;26:1400-3.
8. 8. Filep J, Braquet P, Mózes T. Interactions between platelet-activating factor and prostanoids during mesenteric ischemia-reperfusion-induced shock in the anesthetized dog. Circ Shock 1991;35:1-8.
9. 9. Sasaki M, Herd CM, Page CP. Effect of heparin and a low-molecular weight heparinoid on PAF-induced airway responses in neonatally immunized rabbits. Br J Pharmacol 1993;110: 107-12.
10. 10. Seeds EA, Hanss J, Page CP. The effect of heparin and related proteoglycans on allergen and PAF-induced eosinophil infiltration. J Lipid Mediat 1993;7:269-78.
11. 11. Freire-Maia L, de Matos IM. Heparin and a PAF antagonist (BN-52021) prevents the acute pulmonary edema induced by Tityus Serrulatus scorpion venom in the rat. Toxicon 1993; 31:1207-10.
12. 12. Hassard TH. Understanding Biostatistics. St. Louis: Mosby Year Book; 1991.
13. 13. Doebber TW, Wu MS, Robbins JC, Choy BM, Chang MN, Shen TY. Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats, studies with PAF-receptor antagonist Kadsurenone. Biochem Biophys Res Commun 1985;127:799-808.
14. 14. Sirois MG, Tavares de Lima W, Fernandes AJ, Johnson RJ, Plante GE, Sirois P. Effect of PAF on rat lung vascular permeability: role of platelets and polymorphonuclear leucocytes. Br J Pharmacol 1994;111:1111-6.
15. 15. Bourgain RH, Maes L, Braquet P, Andries R, Touqui L, Braquet M. The effect of 1-O-alkyl-2-acetyl-sn-glycero-3 phosphocholine (PAF-acether) on arterial wall. Prostaglandins 1985; 30:185-97.
16. 16. Rabinovici R, Yue T, Feuerstein G. Platelet-activating factor in cardiovascular stress situations. Lipids 1991;26:1257-63.
17. 17. Haglund U, Iwarson S, Lundberg D. Sepsis, SIRS, MODS: Etiology and Therapy. Borås, Sweden: Centraltryckeriet; 1995.
18. 18. Tucker A, Weir EK, Reeves JT, Grover RF. Pulmonary microembolism: Attenuated pulmonary vasoconstriction with prostaglandins inhibitors and antihistamines. Prostaglandins 1976;11:31-42.
19. 19. Nakahodo K, Saitoh S, Nakamura M, Kosugi T. Histamine release from rabbit platelets by platelet-activating factor (PAF). Jpn J Allergol 1994;43:501-10.
20. 20. Bernat A, Herbert JM. Effect of various drugs on adriamycin-enhanced venous thrombosis in the rat: Importance of PAF. Thromb Res 1994;75:91-7.
21. 22. Hocking D, Ferro TJ, Johnson A. Dextran sulfate and heparin sulfate inhibit platelet-activating factor-induced pulmonary edema. J Appl Physiol 1992;72:179-85.
22. 23. Evans TW, Chung KF, Rogers DF, Barnes PJ. Effect of platelet-activating factor on airway vascular permeability: Possible mechanisms. J Appl Physiol 1987;63:479-84.
23. 24. Lambrecht G, Parnham MJ. Kadsurenone distinguishes between different platelet activating factor receptor subtypes on macrophages and polymorphonuclear leucocytes. Br J Pharmacol 1986;87:287-9.
24. 25. Blank ML, Cress EA, Whittle T, Snyder F. In vivo metabolism of a new class of biologically active phospholipids: 1-alkyll-2-acetyl-sn-glycero-3-phosphocholine, a platelet activating-hypotensive phospholipid. Life Sci 1981;29: 769-75.
25. 26. Benveniste J. Platelet-activating factor, a new mediator of anaphylaxis and immune complex deposition from rabbit and human basophils. Nature 1974;249:581-2.
26. 27. Grigoriadis G, Stewart AG. Albumin inhibits platelet-activating factor (PAF)-induced responses in platelets and macrophages: Implications for the biologically active form of PAF. Br J Pharmacol 1992;107:73-7.
27. 28. Siebeck M, Weipert J, Keser C, Kohl J, Spannagl M, Machleidt W, Schweiberer L. A triazolodiazepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine. J Trauma 1991;31:942-50.